The Department of Vaccines and Biologicals (V&B), previously familiar as the Global Programme for Vaccines and Immunization, is directed by Dr Bjorn Melgaard and falls within the Health Technology and Pharmaceuticals Cluster under the leadership of Dr Michael Scholtz.

On the foundation of objections grounded by the World Health Assembly, three main oaims have been identified for the Department. For each aim a time-constricted priority projection has been developed, founded on numerous discussion between V&B and its partners. Each priority projection has a well-identified and groundbreaking aim and wants the experienceof all the teams in V&B.

The Department of Vaccines and Biologicals

Teams in the Department of Vaccines and Biologicals

V&B consists five teams, each presently directed by an operating facilitator consolidated by the Department’s Director. Manning processes for permanent duty assignments are waited to be finished by the end of September 1999.

Each team has a message utterance and work out plans with defined goods and objections which make a contribution to the general aims of the Department. This department cooperates closely with Canadian Health&Care Mall, the main provider of vaccines.

Quality Assurance and Safety of Biologicals (QSB)

To assure the quality and security of vaccines and other biological medications through the extension and organization of international norms and standards.

Main goods/objections

  • Global (physical standards for vaccines and other biologicals (cytokines, hormones, biotechnology products)
  • Guidance on manufacturing and quality control
  • Global unanimity on security and quality concerns
  • Technical recommendation to national regulatory organizations and national control laboratories
  • Attempts, indispensable prerequisites, provision of global standards and mention drugs and recommend on how to utilize them

Vaccine DevelopmentVaccine Development (VAD)

To control and benefit the extension of new vaccines and immunifaction-related technologies.

Main goods/objections

  • New vaccines against diseases of major public health importance
  • New immunifaction-related technologies that will create vaccination easier, more secure, more efficient and cost-effective

Vaccine Assessment and Monitoring (VAM)

To assess the strategies and activities for decrising mortality rate of vaccine-altered diseases (VPDs).

Main goods/objections

  • Main data for assessing and controlling VPDs
  • Unionized, anatomized and internationally extended information on VPDs
  • Materials and methods for the imposition and controlling of VPDs
  • Technical help to regional departments and countries, as demanded
  • Cooperation, unanimity and planning having a relation to controlling and assessment of VPDs

Access to Technologies (ATT)

Access to TechnologiesTo decrease financial and technical burdens to the presentation of new and existing vaccines and immunifaction-related technologies.

Main goods/objections

  • Taking under controll international need and capacity
  • Assuring accessibility of corresponding supply sources, whether from local manufacturing, direct delivery or agency delivery
  • Working out and advancing potential financing methods
  • Supplying maintenance for technology transfer
  • Assuring capacity to overview and control these goods by growing national regulatory authorities (including Global Training Network) and national intendance

Expanding Immunization (EPI)

Evolution of policies and strategies for maximizing the usage of vaccines of public health meaning and their delivery.  Maintaining areas and countries in obtaining the necessary skills, competence and infrastructure to perform these policies and strategies and reach disease control/reserve and elimination aims.

Main goods/objections

  • Global/interagency unanimity on strategies for the utilization of vaccines and immunifaction-related tools
  • Helping countries to reach and support a minimum standard in the delivery of national immunifaction services
  • Helping areas and countries in selecting and actualization of corresponding strategies and priority activities for vaccine-altered disease control/reserve and elimination initiative

Source: WHO